NEW YORK – Angle announced on Friday that it has signed a supplier agreement with AstraZeneca to develop an androgen receptor (AR) assay to assess prostate cancer treatments.

纽约——Angle周五宣布，已与阿斯利康签署供应商协议，开发雄激素受体（AR）检测方法，以评估前列腺癌的治疗效果。

Under the terms of the deal, in which Angle will receive £550,000 ($693,250), the company will use its Parsortix platform to develop an assay to measure AR status throughout clinical studies and during follow-up, based on circulating tumor cells (CTCs). Development will take place at the firm's Guildford, UK laboratory..

根据交易条款，Angle将获得550000英镑（693250美元），该公司将利用其Parsortix平台开发一种基于循环肿瘤细胞（CTC）的检测方法，用于在整个临床研究和随访期间测量AR状态。开发将在该公司的英国吉尔福德实验室进行。。

Angle expects to complete this project in the first quarter of 2025 and follows another supplier agreement with AstraZeneca, announced last month, to develop and validate a method for the detection of micronuclei in CTCs using its existing DNA damage response assay.

Angle预计在2025年第一季度完成该项目，并遵循上月宣布的与阿斯利康的另一份供应商协议，开发并验证一种使用现有DNA损伤反应测定法检测CTC中微核的方法。

'This is further validation of Angle's Parsortix system which shows potential for long-term large-scale revenues in bringing innovative new cancer drugs to the market,' Angle's CEO Andrew Newland said of the new agreement in a statement. 'We anticipate that success in this first phase of assay development may lead to much larger contracts for use of the assay in clinical trials.'.

Angle首席执行官安德鲁·纽兰（AndrewNewland）在一份声明中谈到新协议时说，这进一步验证了Angle的Parsortix系统，该系统显示出将创新的抗癌新药推向市场的长期大规模收入潜力我们预计，在检测开发的第一阶段取得成功可能会导致在临床试验中使用该检测的合同更大。”。